Home › B-cel lymfoom › Texas › Houston
B-cel lymfoom klinische studies in Houston, TX
16 studies voor B-cel lymfoom zoeken deelnemers op locaties in en rond Houston (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruterenObservatieonderzoek
- Texas Children's Hospital, Houston
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RekruterenFase 3
- Md Anderson Cancer Center, Houston
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
RekruterenFase 2
- MD Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruterenFase 1
- MD Anderson Cancer Center, Houston
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RekruterenFase 2
- M D Anderson Cancer Center, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RekruterenFase 2
- Research Site, Houston
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
RekruterenFase 1/2
- The University of Texas Md Anderson Cancer Center, Houston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RekruterenFase 1/2
- Research Site, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
RekruterenFase 1
- Clinical Trial Site, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RekruterenFase 1/2
- M D Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RekruterenFase 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
RekruterenFase 1
- The University of Texas M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
RekruterenFase 2
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
RekruterenFase 1
- MD Anderson Cancer Center, Houston
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
RekruterenFase 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RekruterenFase 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
B-cel lymfoom studies in andere steden
- New York City, NY19 studies
- Chicago, IL12 studies
- Nashville, TN11 studies
- Philadelphia, PA11 studies
- Rochester, MN10 studies
- Baldwin Park, CA9 studies
- Milwaukee, WI9 studies
- Cleveland, OH9 studies
- Salt Lake City, UT8 studies
- Boston, MA8 studies
- Columbus, OH7 studies
- Pittsburgh, PA7 studies
Andere studies in Houston
- Niet-kleincellige longkanker145 studies
- Borstkanker126 studies
- Kanker (alle vormen)121 studies
- Metastatische kanker104 studies
- Colorectale kanker102 studies
- Eierstokkanker89 studies
- Acute myeloïde leukemie85 studies
- Longkanker78 studies
- Prostaatkanker76 studies
- Endometriumkanker68 studies
- Aldermeesklierkanker61 studies
- Melanoom59 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.